Genesis of the project
Classical chemotherapy is still, in addition to surgery, an essential tool in the hands of an oncologists to treat cancer patients. Nevertheless, its use is generally associated with strong side effects, often low efficacy, relapse, and very often with secondary drug resistance. Current trends in anticancer therapeutics, therefore, seek to develop innovative therapeutic strategies.
Today more and more pharmaceutical companies looking for innovative anti-cancer drug action directed to a defined molecular target tumor cell. Clinical trials of new drugs are always preceded by extensive laboratory tests and preclinical, consisting of a preliminary assessment of activity of the compounds in vitro and then in vivo testing in animal models for the characteristics of pharmacology, pharmacokinetics and bioavailability and tolerability in animals.
Currently, the requirement of the European Union is to conduct these studies in laboratories with GLP standards. At present, in Poland there is no certified laboratories wholesalejeans performing screening tests. The creation of the Integrated Laboratory of Experimental NeoLek-Oncology and Innovative Technology opens the possibility of conducting such research in Poland, and will contribute to lower financial expenses, which pharmaceutical companies must devote to research.
Department of Experimental Oncology, which NeoLek derives from, conducts research on substances with potential anticancer activity since 1969. The Institute has extensive experience in conducting screening studies and employs highly qualified scientists. In addition, the Institute of Immunology and Experimental Therapy, is Poland’s largest collection of cell lines. The collection brings together over 160 reference cell line of human and animal coming from reputable sources. Collection has, among others sets of lines derived from human organ cancers, a line of human and murine vascular endothelial cells, genetically modified tumor and the tumor lines derived resistance to known and used in the clinic treating drugs. This makes it possible to carry out screening of potential drugs for antiproliferative activity against a broad spectrum of tumor cells.